Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Marlise Rachael Luskin, M.D.

Title
Institution
Department
Address
Phone
Fax

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Stern RM, Luskin MR, Clark RP, Miller AL, Loscalzo J. A Headache of a Diagnosis. N Engl J Med. 2018 Aug 02; 379(5):475-479. PMID: 30067932.
    View in: PubMed
  2. Luskin MR. Chronic myeloid leukemia and pregnancy: patient and partner perspectives. Expert Rev Hematol. 2018 Aug; 11(8):597-599. PMID: 30012034.
    View in: PubMed
  3. Luskin MR, DeAngelo DJ. How to treat chronic myeloid leukemia (CML) in older adults. J Geriatr Oncol. 2018 Jul; 9(4):291-295. PMID: 29463446.
    View in: PubMed
  4. Luskin MR, Murakami MA, Manalis SR, Weinstock DM. Targeting minimal residual disease: a path to cure? Nat Rev Cancer. 2018 Apr; 18(4):255-263. PMID: 29376520.
    View in: PubMed
  5. Luskin MR, Abel GA. Management of older adults with myelodysplastic syndromes (MDS). J Geriatr Oncol. 2018 Jul; 9(4):302-307. PMID: 29290596.
    View in: PubMed
  6. Banerjee R, Luskin MR, Loren AW. Late effects of blood and marrow transplantation. Haematologica. 2017 11; 102(11):e465. PMID: 29079647.
    View in: PubMed
  7. Luskin MR, DeAngelo DJ. Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia. Expert Rev Hematol. 2017 12; 10(12):1033-1045. PMID: 29069942.
    View in: PubMed
  8. Luskin MR, Discenza MN, Easter SR, Dal Cin P, Owen R, Ilagan B, Masiello M, Lane AA. Maternal iAMP21 acute lymphoblastic leukemia detected on prenatal cell-free DNA genetic screening. Blood Adv. 2017 Aug 22; 1(19):1491-1494. PMID: 29296790.
    View in: PubMed
  9. Luskin MR, Stone RM. Can Minimal Residual Disease Determination in Acute Myeloid Leukemia Be Used in Clinical Practice? J Oncol Pract. 2017 08; 13(8):471-480. PMID: 28796964.
    View in: PubMed
  10. Luskin MR, DeAngelo DJ. Chimeric Antigen Receptor Therapy in Acute Lymphoblastic Leukemia Clinical Practice. Curr Hematol Malig Rep. 2017 08; 12(4):370-379. PMID: 28656487.
    View in: PubMed
  11. Muffly L, Pasquini MC, Martens M, Brazauskas R, Zhu X, Adekola K, Aljurf M, Ballen KK, Bajel A, Baron F, Battiwalla M, Beitinjaneh A, Cahn JY, Carabasi M, Chen YB, Chhabra S, Ciurea S, Copelan E, D'Souza A, Edwards J, Foran J, Freytes CO, Fung HC, Gale RP, Giralt S, Hashmi SK, Hildebrandt GC, Ho V, Jakubowski A, Lazarus H, Luskin MR, Martino R, Maziarz R, McCarthy P, Nishihori T, Olin R, Olsson RF, Pawarode A, Peres E, Rezvani AR, Rizzieri D, Savani BN, Schouten HC, Sabloff M, Seftel M, Seo S, Sorror ML, Szer J, Wirk BM, Wood WA, Artz A. Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. Blood. 2017 08 31; 130(9):1156-1164. PMID: 28674027.
    View in: PubMed
  12. Honigberg MC, Eshel N, Luskin MR, Shaykevich S, Lipsitz SR, Katz JT. Curricular Time, Patient Exposure, and Comfort Caring for Lesbian, Gay, Bisexual, and Transgender Patients Among Recent Medical Graduates. LGBT Health. 2017 06; 4(3):237-239. PMID: 28418736.
    View in: PubMed
  13. Luskin MR, Cronin AM, Owens RL, DeAngelo DJ, Stone RM, Wadleigh M, Steensma DP, Abel GA. Self-reported sleep disturbance and survival in myelodysplastic syndromes. Br J Haematol. 2017 05; 177(4):562-566. PMID: 28272741.
    View in: PubMed
  14. Dinardo CD, Luskin MR, Carroll M, Smith C, Harrison J, Pierce S, Kornblau S, Konopleva M, Kadia T, Kantarjian H, Wertheim GB, Master SR. Validation of a clinical assay of multi-locus DNA methylation for prognosis of newly diagnosed AML. Am J Hematol. 2017 Feb; 92(2):E14-E15. PMID: 27804182.
    View in: PubMed
  15. Wertheim GBW, Luskin MR, Carroll M, Master SR. Microsphere-Based Assessment of DNA Methylation for AML Prognosis. Methods Mol Biol. 2017; 1633:125-136. PMID: 28735484.
    View in: PubMed
  16. Luskin MR, Carroll M, Lieberman D, Morrissette JJD, Zhao J, Crisalli L, Roth DB, Luger SM, Porter DL, Reshef R. Clinical Utility of Next-Generation Sequencing for Oncogenic Mutations in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2016 11; 22(11):1961-1967. PMID: 27478011.
    View in: PubMed
  17. Luskin MR, Gimotty PA, Smith C, Loren AW, Figueroa ME, Harrison J, Sun Z, Tallman MS, Paietta EM, Litzow MR, Melnick AM, Levine RL, Fernandez HF, Luger SM, Carroll M, Master SR, Wertheim GB. A clinical measure of DNA methylation predicts outcome in de novo acute myeloid leukemia. JCI Insight. 2016 Jun 16; 1(9). PMID: 27446991.
    View in: PubMed
  18. Sloan CE, Luskin MR, Boccuti AM, Sehgal AR, Zhao J, Daber RD, Morrissette JJ, Luger SM, Bagg A, Gimotty PA, Carroll M. A Modified Integrated Genetic Model for Risk Prediction in Younger Patients with Acute Myeloid Leukemia. PLoS One. 2016; 11(4):e0153016. PMID: 27050425; PMCID: PMC4822876.
  19. Luskin MR, Lee JW, Fernandez HF, Abdel-Wahab O, Bennett JM, Ketterling RP, Lazarus HM, Levine RL, Litzow MR, Paietta EM, Patel JP, Racevskis J, Rowe JM, Tallman MS, Sun Z, Luger SM. Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups. Blood. 2016 Mar 24; 127(12):1551-8. PMID: 26755712.
    View in: PubMed
  20. Aikawa V, Porter D, Luskin MR, Bagg A, Morrissette JJ. Transmission of an expanding donor-derived del(20q) clone through allogeneic hematopoietic stem cell transplantation without the development of a hematologic neoplasm. Cancer Genet. 2015 Dec; 208(12):625-9. PMID: 26628205.
    View in: PubMed
  21. Luskin MR, Ganetsky A, Landsburg DJ, Loren AW, Porter DL, Nasta SD, Svoboda J, Luger SM, Frey NV. Nelarabine, cyclosphosphamide and etoposide for adults with relapsed T-cell acute lymphoblastic leukaemia and lymphoma. Br J Haematol. 2016 07; 174(2):332-4. PMID: 26403537.
    View in: PubMed
  22. Luskin MR, Banerjee R, Del Percio S, Loren AW. A Pound of Cure Requires An Ounce (or More) of Prevention: Survivorship and Complications of Therapy for Hematologic Malignancies. Curr Hematol Malig Rep. 2015 Sep; 10(3):225-36. PMID: 26162948.
    View in: PubMed
  23. Luskin MR, Huen AO, Brooks SA, Stewart C, Watt CD, Morrissette JJ, Lieberman DB, Bagg A, Rosenbach M, Perl AE. NPM1 mutation is associated with leukemia cutis in acute myeloid leukemia with monocytic features. Haematologica. 2015 Oct; 100(10):e412-4. PMID: 26113416; PMCID: PMC4591778.
  24. Reshef R, Huffman AP, Gao A, Luskin MR, Frey NV, Gill SI, Hexner EO, Kambayashi T, Loren AW, Luger SM, Mangan JK, Nasta SD, Richman LP, Sell M, Stadtmauer EA, Vonderheide RH, Mick R, Porter DL. High Graft CD8 Cell Dose Predicts Improved Survival and Enables Better Donor Selection in Allogeneic Stem-Cell Transplantation With Reduced-Intensity Conditioning. J Clin Oncol. 2015 Jul 20; 33(21):2392-8. PMID: 26056179; PMCID: PMC4500833.
  25. Luskin MR, Heil DS, Tan KS, Choi S, Stadtmauer EA, Schuster SJ, Porter DL, Vonderheide RH, Bagg A, Heitjan DF, Tsai DE, Reshef R. The Impact of EBV Status on Characteristics and Outcomes of Posttransplantation Lymphoproliferative Disorder. Am J Transplant. 2015 Oct; 15(10):2665-73. PMID: 25988622.
    View in: PubMed
  26. Tsai DE, Luskin MR, Kremer BE, Chung AK, Arnoldi S, Paralkar VR, Nasta SD, Stadtmauer EA, Schuster SJ, Xavier M. A pilot trial of quantitative Epstein-Barr virus polymerase chain reaction in patients undergoing treatment for their malignancy: potential use of Epstein-Barr virus polymerase chain reaction in multiple cancer types. Leuk Lymphoma. 2015 May; 56(5):1530-2. PMID: 25219594.
    View in: PubMed
  27. Wertheim GB, Smith C, Luskin M, Rager A, Figueroa ME, Carroll M, Master SR. Validation of DNA methylation to predict outcome in acute myeloid leukemia by use of xMELP. Clin Chem. 2015 Jan; 61(1):249-58. PMID: 25348669; PMCID: PMC4384518.
  28. Frosch Z, Luskin MR, Landsburg DJ, Schuster SJ, Svoboda J, Loren AW, Porter DL, Stadtmauer EA, Nasta SD. R-CHOP or R-HyperCVAD with or without autologous stem cell transplantation for older patients with mantle cell lymphoma. Clin Lymphoma Myeloma Leuk. 2015 Feb; 15(2):92-7. PMID: 25174772.
    View in: PubMed
  29. Luskin M, Wertheim G, Morrissette J, Daber R, Biegel J, Wilmoth D, Kersun L, King R, Paessler M, Simon C, Aplenc R, Loren A. CLL/SLL diagnosed in an adolescent. Pediatr Blood Cancer. 2014 Jun; 61(6):1107-10. PMID: 24281971.
    View in: PubMed
  30. Luskin MR, Roy DB, Wasik MA, Loren AW. Development of lymphomas containing Epstein-Barr virus after therapy with hyper-CVAD regimen. Clin Lymphoma Myeloma Leuk. 2014 Apr; 14(2):e55-8. PMID: 24393621.
    View in: PubMed
  31. Luskin MR, Campigotto F, Richardson PG, Koreth J, Ghobrial IM, Schlossman RL, Munshi NC, Alyea EP, Soiffer RJ, Warren D, Gannon M, Finn K, Anderson KC, Weller EA, Laubach JP. The impact of ASCT on patients with newly diagnosed multiple myeloma who receive RVD induction. Journal of Hematological Malignancies. 2013; 1(3):41-48.
  32. Laubach JP, Mitsiades CS, Mahindra A, Luskin MR, Rosenblatt J, Ghobrial IM, Schlossman RL, Avigan D, Raje N, Munshi NC, Anderson KC, Richardson PG. Management of relapsed and relapsed/refractory multiple myeloma. J Natl Compr Canc Netw. 2011 Oct; 9(10):1209-16. PMID: 21975917.
    View in: PubMed
  33. Reshef R, Luskin MR, Kamoun M, Vardhanabhuti S, Tomaszewski JE, Stadtmauer EA, Porter DL, Heitjan DF, Tsai de E. Association of HLA polymorphisms with post-transplant lymphoproliferative disorder in solid-organ transplant recipients. Am J Transplant. 2011 Apr; 11(4):817-25. PMID: 21401872; PMCID: PMC3072270.
  34. Reshef R, Vardhanabhuti S, Luskin MR, Heitjan DF, Hadjiliadis D, Goral S, Krok KL, Goldberg LR, Porter DL, Stadtmauer EA, Tsai DE. Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder(?). Am J Transplant. 2011 Feb; 11(2):336-47. PMID: 21219573; PMCID: PMC3079420.
  35. Tilton JC, Manion MM, Luskin MR, Johnson AJ, Patamawenu AA, Hallahan CW, Cogliano-Shutta NA, Mican JM, Davey RT, Kottilil S, Lifson JD, Metcalf JA, Lempicki RA, Connors M. Human immunodeficiency virus viremia induces plasmacytoid dendritic cell activation in vivo and diminished alpha interferon production in vitro. J Virol. 2008 Apr; 82(8):3997-4006. PMID: 18256146.
    View in: PubMed
  36. Tilton JC, Luskin MR, Johnson AJ, Manion M, Hallahan CW, Metcalf JA, McLaughlin M, Davey RT, Connors M. Changes in paracrine interleukin-2 requirement, CCR7 expression, frequency, and cytokine secretion of human immunodeficiency virus-specific CD4+ T cells are a consequence of antigen load. J Virol. 2007 Mar; 81(6):2713-25. PMID: 17182676; PMCID: PMC1865970.
  37. Tilton JC, Johnson AJ, Luskin MR, Manion MM, Yang J, Adelsberger JW, Lempicki RA, Hallahan CW, McLaughlin M, Mican JM, Metcalf JA, Iyasere C, Connors M. Diminished production of monocyte proinflammatory cytokines during human immunodeficiency virus viremia is mediated by type I interferons. J Virol. 2006 Dec; 80(23):11486-97. PMID: 17005663; PMCID: PMC1642603.
  38. Olshen E, Woods ER, Austin SB, Luskin M, Bauchner H. Parental acceptance of the human papillomavirus vaccine. J Adolesc Health. 2005 Sep; 37(3):248-51. PMID: 16109349.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Luskin's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (194)
Explore
_
Co-Authors (29)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
Funded by the NIH/NCATS Clinical and Translational Science Award (CTSA) program, grant number UL1TR001102, and through institutional support from Harvard University, Harvard Medical School, Harvard T.H. Chan School of Public Health, Beth Israel Deaconess Medical Center, Boston Children's Hospital, Brigham and Women's Hospital, Massachusetts General Hospital and the Dana Farber Cancer Institute.